Case Study: a client revives an FDA-rejected rare disease application with Kymanox's enhanced analytics and global clinical expansion

A Kymanox Case Study

Development and Globalization of a Synthetic Peptide Nasal Solution for an Orphan Indication

The Client, a pharmaceutical company, faced significant regulatory and technical challenges in developing a synthetic peptide nasal spray for a rare disease. These hurdles included aligning product development with global standards and reviving an FDA-rejected application. They engaged Kymanox for assistance with clinical and medical affairs, regulatory affairs, and product development services to overcome these obstacles.

Kymanox implemented a comprehensive solution involving enhanced analytical techniques, process optimization, and Design History File remediation. This effort standardized testing, increased manufacturing yields, and established new particulate matter standards for nasal sprays. As a result, Kymanox helped secure commercial manufacturing partners and successfully initiated international clinical studies, advancing the product toward multi-regional approval for the orphan indication.


View this case study…

Kymanox

58 Case Studies